OSLO – Nordic Nanovector presented late Sunday evening (US PST) in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA the data from the phase I study of its lead product candidate Betalutin™, the first Radio-Immuno-Therapy (RIT) targeting the CD37 antigen expressed on lymphoma cells. Betalutin™ confirms its potential role in the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).
“Betalutin™ does appear to be effective and well tolerated in patients with relapsed non-Hodgkin Lymphoma. These preliminary results from the ongoing phase I/II study are very encouraging,” said Dr. Arne Kolstad of Oslo University Hospital, The Norwegian Radium Hospital and principal investigator of the study.